Charles Schwab Investment Management Inc. cut its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 2.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 876,253 shares of the medical research company's stock after selling 23,385 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.58% of Bruker worth $51,366,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in BRKR. Assetmark Inc. boosted its stake in Bruker by 23.7% during the third quarter. Assetmark Inc. now owns 1,729 shares of the medical research company's stock worth $119,000 after acquiring an additional 331 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Bruker by 4.4% during the third quarter. Atria Investments Inc now owns 12,698 shares of the medical research company's stock valued at $877,000 after purchasing an additional 538 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Bruker by 3.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 36,627 shares of the medical research company's stock worth $2,529,000 after purchasing an additional 1,267 shares in the last quarter. Aptus Capital Advisors LLC grew its stake in shares of Bruker by 15.8% in the 3rd quarter. Aptus Capital Advisors LLC now owns 40,522 shares of the medical research company's stock worth $2,798,000 after buying an additional 5,523 shares during the last quarter. Finally, KBC Group NV increased its position in Bruker by 1.8% during the 3rd quarter. KBC Group NV now owns 42,680 shares of the medical research company's stock valued at $2,947,000 after buying an additional 763 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.
Wall Street Analysts Forecast Growth
BRKR has been the topic of several analyst reports. Guggenheim reissued a "buy" rating on shares of Bruker in a report on Monday, February 24th. The Goldman Sachs Group upgraded shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. UBS Group started coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target for the company. Bank of America upped their target price on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Finally, Barclays lowered their price target on Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $70.50.
Get Our Latest Stock Report on BRKR
Bruker Stock Performance
Shares of NASDAQ BRKR traded up $1.02 during trading on Monday, hitting $46.94. The company had a trading volume of 1,328,770 shares, compared to its average volume of 1,283,588. The stock has a 50 day simple moving average of $53.66 and a 200 day simple moving average of $58.36. The firm has a market capitalization of $7.12 billion, a P/E ratio of 61.76, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker Co. has a 12 month low of $44.11 and a 12 month high of $94.86.
Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Monday, March 17th. Bruker's dividend payout ratio is currently 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
